1. Home
  2. FUSB vs CLNN Comparison

FUSB vs CLNN Comparison

Compare FUSB & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$16.35

Market Cap

90.1M

Sector

Finance

ML Signal

N/A

Logo Clene Inc.

CLNN

Clene Inc.

HOLD

Current Price

$5.99

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
CLNN
Founded
1952
2012
Country
United States
United States
Employees
N/A
79
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.1M
85.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FUSB
CLNN
Price
$16.35
$5.99
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$33.75
AVG Volume (30 Days)
5.3K
93.1K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
1.72%
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.64
Revenue Next Year
N/A
$19,516.77
P/E Ratio
$49.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.47
$3.25
52 Week High
$16.50
$13.50

Technical Indicators

Market Signals
Indicator
FUSB
CLNN
Relative Strength Index (RSI) 60.91 51.32
Support Level $15.75 $5.40
Resistance Level N/A $6.71
Average True Range (ATR) 0.19 0.41
MACD 0.02 0.04
Stochastic Oscillator 100.00 65.70

Price Performance

Historical Comparison
FUSB
CLNN

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About CLNN Clene Inc.

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Share on Social Networks: